{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:51:15Z","timestamp":1791298275500,"version":"4.1.0"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            BAL30376 is a triple combination comprising a siderophore monobactam,\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"genpept\" xlink:href=\"BAL19764\">BAL19764<\/jats:ext-link>\n            ; a novel bridged monobactam,\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"genpept\" xlink:href=\"BAL29880\">BAL29880<\/jats:ext-link>\n            , which specifically inhibits class C \u03b2-lactamases; and clavulanic acid, which inhibits many class A and some class D \u03b2-lactamases. The MIC\n            <jats:sub>90<\/jats:sub>\n            was \u22644 \u03bcg\/ml (expressed as the concentration of\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"genpept\" xlink:href=\"BAL19764\">BAL19764<\/jats:ext-link>\n            ) for most species of the\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            family, including strains that produced metallo-\u03b2-lactamases and were resistant to all of the other \u03b2-lactams tested. The MIC\n            <jats:sub>90<\/jats:sub>\n            for\n            <jats:italic>Stenotrophomonas maltophilia<\/jats:italic>\n            was 2 \u03bcg\/ml, for multidrug-resistant (MDR)\n            <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n            it was 8 \u03bcg\/ml, and for MDR\n            <jats:italic>Acinetobacter<\/jats:italic>\n            and\n            <jats:italic>Burkholderia<\/jats:italic>\n            spp. it was 16 \u03bcg\/ml. The presence of the class C \u03b2-lactamase inhibitor\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"genpept\" xlink:href=\"BAL29880\">BAL29880<\/jats:ext-link>\n            contributed significantly to the activity of\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"genpept\" xlink:href=\"BAL30376\">BAL30376<\/jats:ext-link>\n            against strains of\n            <jats:italic>Citrobacter freundii<\/jats:italic>\n            ,\n            <jats:italic>Enterobacter<\/jats:italic>\n            species,\n            <jats:italic>Serratia marcescens<\/jats:italic>\n            , and\n            <jats:italic>P. aeruginosa<\/jats:italic>\n            . The presence of clavulanic acid contributed significantly to the activity against many strains of\n            <jats:italic>Escherichia coli<\/jats:italic>\n            and\n            <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n            that produced class A extended-spectrum \u03b2-lactamases. The activity of\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"genpept\" xlink:href=\"BAL30376\">BAL30376<\/jats:ext-link>\n            against strains with metallo-\u03b2-lactamases was largely attributable to the intrinsic stability of the monobactam\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"genpept\" xlink:href=\"BAL19764\">BAL19764<\/jats:ext-link>\n            toward these enzymes. Considering its three components,\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"genpept\" xlink:href=\"BAL30376\">BAL30376<\/jats:ext-link>\n            was unexpectedly refractory toward the development of stable resistance.\n          <\/jats:p>","DOI":"10.1128\/aac.01370-10","type":"journal-article","created":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T04:17:52Z","timestamp":1295410672000},"page":"1510-1519","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Properties of BAL30376, a \u03b2-Lactam and Dual \u03b2-Lactamase Inhibitor Combination with Enhanced Activity against Gram-Negative Bacilli That Express Multiple \u03b2-Lactamases"],"prefix":"10.1128","volume":"55","author":[{"given":"Malcolm G. P.","family":"Page","sequence":"first","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., CH-4005 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clothilde","family":"Dantier","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., CH-4005 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Desarbre","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., CH-4005 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u0301range\u0300re","family":"Gaucher","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., CH-4005 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Gebhardt","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., CH-4005 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schmitt-Hoffmann","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., CH-4005 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.4.851"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.11.012"},{"key":"e_1_3_2_5_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2006"},{"key":"e_1_3_2_6_2","unstructured":"Antimicrobial activity of novel monobactams poster F1-351. 2007"},{"key":"e_1_3_2_7_2","first-page":"160","volume":"23","year":"2009","unstructured":"Drawz, S., and R. A. Bonomo. 2009. Three decades of \u03b2-lactamase inhibitors. Clin. Microbiol. Rev. 23:160-201.","journal-title":"Clin. Microbiol. Rev."},{"key":"e_1_3_2_8_2","unstructured":"Comparative in vitro activity of PTX2416 a dihydroxypyridone monobactam against Gram-negative clinical isolates poster F-552. 2003"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.29.3334"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm980023c"},{"key":"e_1_3_2_11_2","first-page":"821","volume":"22","year":"1982","unstructured":"Jacobus, N. V., M. C. Ferreira, and M. Barza. 1982. In vitro activity of aztreonam, a monobactam antibiotic. Antimicrob. Agents Chemother. 22:821-838.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_12_2","unstructured":"PTX 2416 a dihydroxypyridone monobactam vs. Pseudomonas aeruginosa strains with characterised resistances poster F-554. 2003"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2006.07.008"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki080"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10534-009-9219-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.2.235"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2950295"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1054\/drup.2000.0137"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01525-09"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/522287"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867023370031"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/499819"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2005.08.014"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.145.1.156-163.1981"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-8579(95)00058-5"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01370-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01370-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:28:15Z","timestamp":1645486095000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01370-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1128\/AAC.01370-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.01370-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"2010-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-01-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}